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escalation thresholds influences predicted costs and quality adjusted life expec-
tancy (QALE) in T2DM economic evaluations. Methods: This study used the IMS 
Core Diabetes Model (CDM), a validated and established diabetes model, to evaluate 
the cost effectiveness of metformin+ sulphonylurea (M+S) compared to metformin 
+ DPP-4 (M+D). Baseline HbA1c was set to 8.0% (non-sampled scenario) with stand-
ard error of 0.8 (sampled scenario). Efficacy data for dual therapy was sourced from a 
published systematic review; HbA1c and BMI changes of -0.8% and 0.199kg/m2 (M+D) 
and -0.79% and 0.707kg/m2 (M+S) respectively were applied. Insulin rescue therapy 
was applied to both arms at HbA1c thresholds of 6.5%, 7.0% 7.5%. The model was 
run over a lifetime and costs (US$) and benefits were discounted at 3.5%. Results: 
Total incremental costs were $7,667, $9,571 and $11,644 for M+D versus M+S using 
sampled baseline HbA1c for therapy escalation thresholds of 6.5%, 7.0% 7.5% respec-
tively; and were $5,258, $2311 and $206 lower using non-sampled values, respec-
tively. A similar pattern was observed for QALE, in which incremental QALE gains 
were 85%, 42% and 1% lower with non-sampled compared to sampled baseline 
HbA1c for escalation thresholds of 6.5%, 7.0% 7.5% respectively. ConClusions: 
The importance of probabilistic analysis within cost effectiveness models extends 
beyond quantifying the effects of parameter uncertainty. When treatment decision 
rules are dependent on patient attributes that are subject to variability (such as 
HbA1c) then failing to accommodate this within the model can significantly bias 
predicted costs and QALE.
PRM99
MaRkov Models in non Metastatic PRostate canceR – availability of 
inPut factoRs and stRuctuRuRal unceRtainty
Jacobsen J.
LSHTM, Nevlunghavn, Norway
objeCtives: This study aims at reviewing structural differences in Markov Models 
comparing different treatment strategies for Non-Metastatic Prostate Cancer related 
to scope, time-horizon, perspective, assumptions and the selection of parameters 
for the model. Methods: There is an abundant literature on Prostate Cancer. There 
are however few well performed RCT’s comparing different options for management 
for NMPCa.[1] Due to the lack of conclusive clinical evidence on the best treatment 
for localised prostate there has been a considerable interest in the modelling of 
prostate cancer in decision analytic models and economic evaluation.[2] The lit-
erature review in this paper focuses on the limited number of papers on economic 
evaluation related to the condition. In addition there are several articles presenting 
Markov Models. The evaluation was based on selected items from “Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS)”. Results: In NMPCa 
there are Markov models ranging from two to five health states [9]. The choice of 
model originates from the underlying assumptions, the aim/scope of the study or 
the availability of data to feed into the model. The insufficient clinical evidence 
and few preference based studies of health state values where the most influen-
tial elements in structuring the models Little attention is paid to the structural 
differences in the analysis and the discussions in the available papers. Structural 
uncertainty is viewed as external to the model and difficult to evaluate unless the 
structural choices are made transparent.[10]. ConClusions: Models in NMPCa 
differ in complexity and structure. The ability to evaluate the use of different models 
is highly dependent on transparency in the different building blocks. The CHEERS 
framework provided a useful tool in the evaluation input factors and the different 
Markov Model structures,
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objeCtives: Particularly in the context of HTA evaluations where both post-mar-
keting and pre-marketing data may be considered, the evidence to be synthesized 
can be sparse, partial and heterogeneous for safety outcomes. The Bayesian option 
has increasingly appeared as an unrivalled option for such challenging evidence 
synthesis cases but implementation in practice may be questioned. This work aims 
at determining how Bayesian meta-analysis or mixed treatment comparison of 
safety data can be optimized especially regarding the choice of prior distributions 
and model parameterization. Methods: Based on the latest developments from 
the DIA working group on Bayesian methods for safety data applied to specific 
real-world cases of both direct meta-analysis and mixed treatment comparisons 
(MTC), different model parameterizations and different forms of informative and 
non-informative prior distributions are tested, with various weights allocated to the 
clinical data vs. the observational information. Results: As opposed to the NICE 
parameterization of network meta-analysis, the 2-way predictor parameterization 
of MTC as proposed by the DIA working group provides more robust analysis based 
on non-informative priors. In the case of informative prior results, the most robust 
option was seen for equal total weight of clinical vs. observational data. Results 
of all meta-analyses appeared to be consistent across different model and prior 
specifications, even with low number of studies (< 10). ConClusions: Bayesian evi-
dence synthesis can leverage all available information in a robust manner for both 
direct and indirect comparisons, with fair quantification of uncertainty. Specific 
guidance on MTC model parameterization for safety data could complement the 
current NICE guidelines.
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objeCtives: To analyse the half-cycle correction and its effect on the final results 
of Markov models. Methods: In our analysis we focus on the half-cycle correction, 
which is a method used to deal with the inaccuracy caused by inadequate cycle 
marised recommendations on appropriate evidence sources for different model 
parameters in a narrative manner. Additionally, information on advantages and 
disadvantages of sources, on evidence identification methods and on data quality 
issues was extracted. Results: Twenty-eight documents fulfilled our inclusion 
criteria. We identified a large variety of evidence sources for informing model 
parameters on clinical effect size, natural history of disease, resource use, unit 
costs and health state utility values. They comprise research and non-research 
based sources. The documents do not provide structured advice on the hierarchy 
of evidence and on the limitations of evidence sources. The information is pre-
sented fragmentarily and is not tailored to specific model types. ConClusions: 
The usability of guidelines and manuals for modelling could be improved by 
addressing the issue of appropriate evidence sources in a more structured and 
comprehensive format.
PRM96
Modelling unceRtain futuRe events in cost-effectiveness analysis
Mahon R.
University of York, York, UK
objeCtives: When the appropriate time horizon exceeds the evidence time 
horizon in a cost-effectiveness decision model, numerous uncertainties arise. 
One potential source of uncertainty is that of a possible future event that may 
affect one or more model parameters, e.g. a price shock or the emergence of 
a new comparator. These uncertain future events (UFEs) are rarely accounted 
for in health technology assessment and there is a dearth of guidance regard-
ing how they should be modelled. The objective of this study is to describe the 
circumstances under which UFEs could meaningfully impact cost-effectiveness 
estimates and to explore and demonstrate appropriate modelling techniques 
using a motivating example. Methods: Drawing on examples from HTA and 
other relevant literature, a framework is proposed to outline: when to take 
explicit account of uncertain future events for the purposes of reimbursement 
decisions, how different future events may affect value-of-information analysis 
and what modelling methods are likely to be useful when incorporating UFEs. 
Taking the example of a decision model seeking to estimate the cost-effective-
ness of an early interventional strategy for patients with non-ST-elevation acute 
coronary syndrome, a future price change is simulated and the framework is 
applied. Results: UFEs are shown to impact ‘accept or reject’ reimbursement 
decisions only in very specific circumstances where there is the potential to 
incur irrecoverable costs, whereas their role in value-of-information analysis is 
invariable. The applied example shows that the reimbursement recommenda-
tion for future populations may change with the occurrence of the future event 
and that there is value in reducing the uncertainty regarding the nature of the 
future event. ConClusions: UFEs will only impact expected costs-effectiveness 
sunder specific and rare circumstances. When it is appropriate to include a future 
event in a decision model, the uncertainty surrounding its likelihood, timing and 
magnitude should also be quantified.
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objeCtives: Modelling for cost-effectiveness studies often relies upon the use of 
spreadsheets. However, research has shown that approximately 90% of spread-
sheets contain technical errors. Furthermore, cost-effectiveness models rely on 
accurate transcription between many data sources, which increases the risk of 
errors further. The objective of this analysis was to ascertain the incidence of 
reported technical errors in cost-effectiveness models submitted to NICE as part of 
the Single Technology Assessment (STA) programme, which are subject to rigorous 
assessment by Evidence Review Groups (ERGs). Methods: NICE guidance docu-
ments were searched for a wide range of technical error types using the HTAinsite 
database. Reports were included if the ERG had identified technical errors in the 
manufacturer’s submission and this had been noted at committee level. Included 
appraisals were analysed to identify categories of errors identified. Results: Of 
the 102 completed STA Guidance documents searched, 39 appraisals met the inclu-
sion criteria of the study, representing a technical error incidence of 38.2% (95% CI: 
28.8 – 48.4%). Within these studies, 47 errors were identified in the following areas: 
computation (47%), logic (17%), transcription (13%) and data handling (9%). Error 
causes could not be determined in 15% of cases. The magnitude of effect caused by 
technical errors was difficult to determine, because corrected models often include 
additional changes to parameters or model structure. ConClusions: The inci-
dence of technical errors identified in the STA programme was lower than has 
previously been observed in studies of spreadsheet validity although this analysis 
assumes that ERG groups will identify all technical errors. The true incidence of 
errors may be higher than reported by this analysis. Use of best-practice methods 
and increased awareness of the causes and identification of technical errors may 
help to reduce their pervasiveness.
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objeCtives: Due to the progressive nature of type 2 diabetes mellitus (T2DM), 
patients inevitably require therapy escalation or intensification. In health economic 
analyses, sampling input parameters is routinely undertaken for probabilistic analy-
sis but non-sampled analysis (mean values) is still commonplace. The objective of 
this study was to assess how sampling baseline HbA1c in combination with therapy 
